The biosimilar Hyrimoz showed similar flare rates to Humira, but 25% of patients experienced adverse events, mainly injection site reactions. Injection pain, linked to Hyrimoz's citrate content and ...
Both the high-concentration and low-concentration versions of adalimumab-adaz (Hyrimoz) injection will launch in July, along with a wave of other biosimilars to Humira (reference adalimumab). Sandoz ...
(RTTNews) - Sandoz announced the European Medicines Agency has accepted the application for high concentration formulation 100 mg/mL of its biosimilar Hyrimoz for regulatory review. The company noted ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results